Peregrine Pharmaceuticals, Inc. - Investor Relations

Main menu module goes here

Search the Investors Section

Contact menu module goes here

Home > Investors > Investor Relations

Investor Relations

View all » Recent Releases

May 20, 2013
Peregrine Pharmaceuticals Reaches Agreement With FDA on a Phase III Trial Design for Bavituximab in Second-Line Non-Small Cell Lung Cancer

May 16, 2013
Peregrine Pharmaceuticals' Immunotherapy Bavituximab to Be Highlighted in Three Clinical Data Presentations at 2013 ASCO Annual Meeting

View all »Events & Presentations

May 31, 2013
2013 ASCO Annual Meeting, McCormick Place, Chicago, IL

Transfer Agent
Integrity Stock Transfer 3265 E. Warm Spring Rd. Las Vegas, NV 89120 Telephone: (702) 317-7757 Toll Free: (877) 317-7757 Fax: (702) 796-5650 Email: stock@integritynevada.net

Stock Quote

Ticker:	PPHM
Exchange:	NASDAQ
Last Price:	1.58
Change:	0.08
Volume:	4,410,400
Open:	1.70
Previous Close:	1.66

Contacts
Peregrine Pharmaceuticals, Inc. 14282 Franklin Avenue, Tustin, CA 92780 Phone: 714-508-6000 Fax: 714-838-5817 info@peregrineinc.com	Investor Relations/Corporate Communications info@peregrineinc.com Phone: 800-987-8256

Print

E-mail

Copyright © 2003-2013 Peregrine Pharmaceuticals Inc., All Rights Reserved	Disclaimer Safe Harbor